2003
DOI: 10.1007/s10038-003-0108-1
|View full text |Cite
|
Sign up to set email alerts
|

Identification of a novel splice site mutation of CLCN5 gene and characterization of a new alternative 5’ UTR end of ClC-5 mRNA in human renal tissue and leukocytes

Abstract: Mutations in the CLCN5 gene have been detected in DentÕs disease and its phenotypic variants (X-linked recessive nephrolithiasis, X-linked recessive hypophosphatemic rickets, and idiopathic low-molecular-weight proteinuria of Japanese children). DentÕs disease is a tubular disorder characterized by lowmolecular-weight proteinuria, and nephrolithiasis associated with nephrocalcinosis and hypercalciuria. ClC-5 is the first chloride channel for which a definitive role in the trafficking and acidification-dependen… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

3
20
0

Year Published

2005
2005
2020
2020

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 19 publications
(23 citation statements)
references
References 27 publications
3
20
0
Order By: Relevance
“…The same expectedsize products were observed in both the blood and the kidney RNA samples (results not shown). Forino et al (2004) have also shown that the CLCN5 splicing patterns in leukocytes and kidney biopsies of normal individuals are the same. We therefore considered that blood cells were a suitable source of RNA to study the effect of CLCN5 mutations on pre-mRNA splicing.…”
Section: Resultsmentioning
confidence: 80%
“…The same expectedsize products were observed in both the blood and the kidney RNA samples (results not shown). Forino et al (2004) have also shown that the CLCN5 splicing patterns in leukocytes and kidney biopsies of normal individuals are the same. We therefore considered that blood cells were a suitable source of RNA to study the effect of CLCN5 mutations on pre-mRNA splicing.…”
Section: Resultsmentioning
confidence: 80%
“…The ideal source of RNA to study the effect of mutations on CLCN5 pre-mRNA splicing would be kidney biopsies from patients. However, as this source is not always available, one can use RNA obtained from lymphocytes, which has been shown to be valid for this type of study (Forino et al 2004;ClaverieMartin et al 2005).…”
Section: Resultsmentioning
confidence: 99%
“…Therefore, it has been suggested that, in order to determine the full consequences of a mutation in disease, each mutation should be functionally assessed for its potential effect on splicing (Pagani and Baralle 2004). Until now, only a few CLCN5 mutations affecting pre-mRNA splicing have been described, and only in some cases has the effect been confirmed by mRNA analysis (Morimoto et al 1998;Yamamoto et al 2000;Claverie-Martin et al 2003Forino et al 2004).…”
Section: Introductionmentioning
confidence: 99%
“…ClC-5 is expressed in the kidney, particularly in proximal tubular cells and intercalated collecting duct cells. The human CLCN5 gene, spanning about 170 kb of genomic DNA on chromosome Xp11.23/p11.22, consists of 17 exons including 11 coding exons (2-12) and 6 different 5′ alternatively used exons (5′UTR), some remaining untranslated [1-4]. Transcripts including the untranslated exon 1a (NM_000084.4: mRNA variant 3) [2] or 1b (NM_001282163.1: mRNA variant 4) [3] are spliced to exon 2 and contain the start sequence ATG.…”
Section: Introductionmentioning
confidence: 99%
“…Transcripts including the untranslated exon 1a (NM_000084.4: mRNA variant 3) [2] or 1b (NM_001282163.1: mRNA variant 4) [3] are spliced to exon 2 and contain the start sequence ATG. A third mRNA comprises a larger exon 1b and retains intron 1 (exon 1b1) (alternative mRNA variant 4) [4]. Subsequently, two additional long transcripts due to alternative splicing of exon II and including exons I to IV have also been identified (NM_001127899.3: mRNA variant 1 and NM_001127898.3: mRNA variant 2) [5].…”
Section: Introductionmentioning
confidence: 99%